Moleculin Biotech (MBRX) Cash from Operations (2016 - 2025)
Moleculin Biotech (MBRX) posted quarterly Cash from Operations of 5366000.0 for Q4 2025, down 5.57% year-over-year from 5682370.42 in Q4 2024, and up 25.71% quarter-over-quarter from 7223000.0 in Q3 2025.
Moleculin Biotech (MBRX) Cash from Operations (2016 - 2025) Analysis & Trends
Moleculin Biotech's Cash from Operations history runs 10 years deep, the most recent figure standing at 5366000.0 for Q4 2025.
- In Q4 2025, Cash from Operations fell 5.57% year-over-year to 5366000.0; the TTM figure through Dec 2025 stood at 22735000.0 (up 4.72% YoY), while the FY2025 annual figure was 22735000.0, up 4.72% from the prior year.
- Cash from Operations for Q4 2025 stood at 5366000.0, up from 7223000.0 in the prior quarter.
- The five-year high for Cash from Operations was 3600000.0 in Q1 2021, with the low at 8006000.0 in Q2 2022.
- The 5-year median for Cash from Operations is 5765500.0 (2024), against an average of 5841350.0.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations slumped 76.7% in 2022, then soared 35.97% in 2023.
- Moleculin Biotech's Cash from Operations stood at 4307000.0 in 2021, then tumbled by 68.47% to 7256000.0 in 2022, then soared by 32.51% to 4897000.0 in 2023, then dropped by 3.8% to 5083000.0 in 2024, then fell by 5.57% to 5366000.0 in 2025.
- Business Quant data shows MBRX's Cash from Operations at 5366000.0 in Q4 2025, 7223000.0 in Q3 2025, and 5582000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.37 Mn |
| Dec 31, 2025 | -5.37 Mn |
| Sep 30, 2025 | -7.22 Mn |
| Sep 30, 2025 | -7.22 Mn |
| Jun 30, 2025 | -5.58 Mn |
| Jun 30, 2025 | -5.58 Mn |
| Mar 31, 2025 | -4.56 Mn |
| Mar 31, 2025 | -4.56 Mn |
| Dec 31, 2024 | -5.08 Mn |
| Dec 31, 2024 | -5.08 Mn |
| Sep 30, 2024 | -6.11 Mn |
| Sep 30, 2024 | -6.11 Mn |
| Jun 30, 2024 | -5.95 Mn |
| Jun 30, 2024 | -5.95 Mn |
| Mar 31, 2024 | -6.72 Mn |
| Mar 31, 2024 | -6.72 Mn |
| Dec 31, 2023 | -4.90 Mn |
| Dec 31, 2023 | -4.90 Mn |
| Sep 30, 2023 | -7.55 Mn |
| Sep 30, 2023 | -7.55 Mn |